Baseline characteristics of patients recurring after open or laparoscopic radical hysterectomy after propensity-score matching
| Patients recurring after open abdominal radical hysterectomy (n=70) | Patients recurring after laparoscopic radical hysterectomy (n=35) | P value | |
| Age (years) | 45 (25–68) | 45 (25–82) | 0.89 |
| Body mass index (kg/m2) | 23.1 (15.7–33.3) | 22.4 (15.8–39.8) | 0.77 |
| Comorbidity | 14 (20%) | 6 (17%) | 0.79 |
| Histotype | |||
| Squamous cell | 59 (84%) | 24 (68%) | 0.15 |
| Adenosquamous | 3 (4%) | 4 (11%) | |
| Adenocarcinoma | 8 (11%) | 7 (20%) | |
| FIGO stage | |||
| IB1 | 29 (41%) | 15 (43%) | 1.00 |
| IB2 | 16 (23%) | 7 (20%) | 0.84 |
| IIA | 13 (19%) | 7 (20%) | 1.00 |
| IIB | 12 (17%) | 6 (17%) | 1.00 |
| FIGO grade | |||
| G1/2 | 25 (35%) | 16 (46%) | 0.39 |
| G3 | 45 (65%) | 19 (54%) | |
| Tumor size at diagnosis | |||
| ≤2 cm | 10 (14%) | 7 (20%) | 0.45 |
| >2 cm | 60 (86%) | 28 (80%) | |
| Neoadjuvant chemotherapy | 25 (35%) | 11 (31%) | 0.69 |
| Absence of residual disease in patients having neoadjuvant chemotherapy | 1/25 (4%) | 0/11 (0%) | 1.00 |
| Lymphovascular space invasion | 26 (37%) | 12 (34%) | 1.00 |
| Positive nodes | 28 (40%) | 10 (28%) | 0.28 |
| Adjuvant treatments | 57 (81%) | 26 (74%) | 0.44 |
| Chemotherapy | 4 (7%) | 3 (11%) | 0.67 |
| Radiotherapy | 44 (77%) | 15 (53%) | 0.11 |
| Radiochemotherapy | 9 (15%) | 8 (34%) | 0.14 |
| Adjuvant treatments in patients after neoadjuvant chemotherapy plus surgery | 20 (29%) | 6 (17%) | 0.23 |
FIGO, International Federation of Gynecology and Obstetrics.